A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy

Summary:
For subjects with kidney cancer known as renal cell carcinoma (RCC), that is localized or contained within a specific area of the kidney, the current standard treatment is surgical removal of certain sections of the kidney that contains the primary tumor.  Researchers want to further evaluate the effectiveness of pazopanib in reducing cancer recurrence (tumor re-growth) when taken after the standard surgical removal of sections of the kidney containing the primary tumor.  Pazopanib is a drug that disrupts cell functions which are believed to promote cancer cell growth.  Previous clinical studies of cancer patients taking pazopanib have shown positive outcomes. 

Eligibility and Treatment Plan:

1. Diagnosis of renal cell carcinoma with clear-cell or predominant clear-cell histology
2. Subjects with non-metastatic disease (M0) that fulfill specific combinations of pathological staging as detailed in the protocol
3. Subjects must be at least 18 years

Please call for more information